Divis Laboratories pledges Rs 15 bn for capexIllustrative image – not actual.
Divis Laboratories, an active pharmaceutical ingredients (APIs) and drug intermediates maker, has earmarked Rs 15 billion as capex. The company aims to spend the money at its existing facilities in the next 15 months to more than make up for the delayed greenfield project plans in Kakinada, Andhra Pradesh.

The company will be investing Rs six billion each at its Unit-2 of Vizag SEZ in Andhra Pradesh and Unit-1 of its Nalgonda SEZ in Telangana to build additional capacities, besides spending another Rs three billion for debottlenecking of Unit-2 in Vizag.

The capacity expansion is expected to be completed by the end of calendar year 2019. At present, the company operates four multi-purpose manufacturing facilities out of these two sites.

The brownfield expansion was taken up in order to cater to the increasing opportunities in generic and big pharma business. The company is engaged in the manufacturing of key ingredients used to make final products by the formulations companies.

← All latest storiesBack to top →